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Summary
Mesothelioma is a malignant tumour of pleura 
and other serosal tissues. it arises many years 
after asbestos exposure. There is currently no 
highly effective therapy and the median survival 
is approximately 10–12 months from diagnosis. 
Most patients cannot be treated surgically due to 
the advanced stage of the disease at diagnosis 
or are unfit for radical surgery. New antifolate 
drugs (pemetrexed or raltitrexed) in combination 
with platinum are associated with longer median 
survival than platinum alone, an increase which 
averages about three months. radiation therapy 
is limited by its toxicity to the underlying lung, 
but newer field and dose planning methods are 
under investigation. Mesothelioma presents 
major challenges for the palliative management 
of dyspnoea, pain, and cancer cachexia syndrome. 
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introduction
Mesothelioma is an aggressive tumour of serosal surfaces, 
most commonly the pleura, associated with exposure to 
asbestos often many years previously. In Australian men the 
age standardised incidence of mesothelioma rose from 2.3 new 
cases per 100 000 population in 1982 to 5.4 in 2007. The peak 
incidence is predicted to occur within the next decade and the 
2011 Australian caseload is estimated to be 990 new cases. 
Mesothelioma is resistant to classical anticancer treatments 
with a median survival from diagnosis of approximately 10–12 
months. Highly effective therapy for the disease remains elusive.
Surgical treatment
The role of surgery alone in mesothelioma is debatable. non-
randomised studies of radical trimodality treatment (extrapleural 
pneumonectomy, chemotherapy and radiotherapy) report median 
survival rates of 9.4 to 27.5 months. Extended survival is more 
likely in those with complete resections, epithelial histology, and 
without involvement of extrapleural nodes. This management 
approach may be suitable for highly selected patients with good 
functional status who have Stage 1 or 2 epithelioid tumour 
subtypes and can be treated in a centre with specific surgical 
expertise, but it is generally unsuitable for the majority of patients. 
Key trials underpinning current 'standard' 
chemotherapy
Establishing a 'standard' active chemotherapy for mesothelioma 
has been difficult. There are few randomised trials, they involve 
small numbers of patients and the response to treatment is 
difficult to measure. There is difficulty comparing trial results 
because patients have different stages of disease and different 
histopathology subtypes. Response rates greater than 15% 
(based on tumour dimensions) have been reported for several 
single drugs including gemcitabine, platinum, vinorelbine, 
several anthracyclines (such as doxorubicin), and several 
antifolate drugs (such as pemetrexed).1 Platinum-containing 
combinations generally produced higher response rates than 
single drug therapy, for example cisplatin plus gemcitabine 
response rates ranged from 15% to 48% in three non-
randomised trials. However, there are few direct randomised 
comparisons of single drugs versus combinations.
There is only one randomised trial of chemotherapy versus  
no chemotherapy. This multicentre trial was initially designed  
with two older chemotherapy regimens – either four cycles of  
mitomycin, vinblastine and cisplatin or weekly vinorelbine for  
12 weeks. Because of slow recruitment of patients these regimens  
were combined in a post hoc analysis of the primary outcome of 
overall survival and compared with active symptom control. A 
total of 409 patients were randomised. The median survival with 
chemotherapy (8.5 months) was not significantly different from 
that with active symptom control (7.6 months), and there was 
no evidence of a difference in quality of life.2 Active symptom 
control was as recommended by the British Thoracic Society 
at the time and did not include chemotherapy, however 15% of 
patients in the active symptom control arm and 14% of those 
in the chemotherapy arms received chemotherapy other than 
the protocol chemotherapy. The relative lack of effectiveness of 
platinum based chemotherapy may have been affected by the 
limited dose and duration of treatment in this trial.
Antifolate combinations
A randomised single-blind study of 456 patients found an 
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improved response rate (41% vs 16.7%) and a longer median 
survival in those treated with cisplatin plus pemetrexed 
(12.1 months) versus cisplatin alone (9.3 months). Both 
haematological (grade 3/4) and non-laboratory toxicity were 
significantly more frequent in the combination arm than in 
the cisplatin only arm (anaemia 5% vs 0%, neutropenia 28% 
vs 2.3%, thrombocytopenia 6% vs 0%, vomiting 13% vs 3%, 
diarrhoea 4% vs 0%, dehydration 4% vs 0.5%, and stomatitis 4% 
vs 0%). Supplements of vitamin B12 and folic acid reduced the 
haematologic toxicity of pemetrexed/cisplatin including rates 
of febrile neutropenia and infection, and non-haematological 
toxicity including nausea and vomiting without reducing the 
efficacy of the combination.3 Superior pain, dyspnoea, and 
fatigue scores, as well as stabilisation of global quality of life 
and activity level scores were subsequently reported for patients 
on the combination arm of this study. A similarly designed 
study of platinum with raltitrexed (a specific inhibitor of 
thymidilate synthase) also showed a similar survival advantage 
for the combination compared with cisplatin alone, as well as 
no deterioration in health related quality of life over time in 
either arm.4  
Although there is no published randomised study of single drug 
platinum versus no chemotherapy, it is assumed that platinum 
alone is either active or at least not detrimental. These studies 
showing a survival benefit and improved quality of life for patients 
treated with antifolates plus platinum over platinum alone, 
underpin the Australian approval of pemetrexed in combination 
with platinum as first-line chemotherapy for mesothelioma.
Further experience with antifolates in mesothelioma was gained 
in expanded access programs in the USA and Europe. These 
non-randomised studies report that median survival for patients 
given platinum with pemetrexed is longer than with pemetrexed 
alone in both first- and second-line settings. However, there is 
a possible bias that fitter patients may have been selected for 
combination chemotherapy rather than pemetrexed alone.5
Combination regimen
For patients with good performance status and adequate 
end-organ function, the standard treatment in Australia is 
pemetrexed 500 mg/m2 as a 10-minute intravenous infusion 
followed by cisplatin 75 mg/m2 over two hours on day one of 
21-day cycles. Pharmaceutical costs are approximately  
$19 000 for six cycles of treatment. Patients must take folic 
acid 350–1000 microgram daily (usually 500 microgram) and 
be given vitamin B12 1000 microgram intramuscularly seven 
days before the start of treatment repeated nine-weekly during 
treatment to reduce haematological and non-haematological 
toxicity. Dexamethasone is given for three days starting the day 
before pemetrexed therapy to reduce the risk of skin rash.
A single small randomised study of chemotherapy given 
immediately after diagnosis or delayed until symptoms 
progressed showed that the duration of controlled symptoms 
and survival were longer in patients receiving immediate 
treatment.6 Although the difference of four months in median 
survival was not statistically significant, it suggests that there is 
no advantage in delaying treatment. 
There is a lack of data concerning optimal duration of treatment –  
patients in the single-blind study received 1–12 cycles, with 
a median of six.3 Treatment is usually given for a total of six 
cycles or ceased earlier if the patient develops progressive 
disease or unacceptable toxicity. Carboplatin may be substituted 
for cisplatin in patients with mild to moderately impaired renal 
function (response rates were similar to the cisplatin-based 
combination).7 The International Expanded Access program 
also included carboplatin.8 Platinum drugs and pemetrexed are 
contraindicated in severe renal insufficiency.
Second-line and maintenance treatment
To date there is one randomised study of treatment after 
failure of first-line chemotherapy. Second-line treatment with 
pemetrexed was associated with prolonged progression-free 
survival compared with best supportive care (median 3.6 
months vs 1.5 months),9 however few patients had received 
pemetrexed in their first-line chemotherapy. Although there 
was no significant increase in the primary endpoint of overall 
survival in the pemetrexed arm, this may have been affected by 
the higher proportion of patients in the best supportive care arm 
who received post-discontinuation chemotherapy (including 
pemetrexed in some cases). Several phase II studies have been 
reported, but do not support recommendation of a particular 
treatment. For maintenance treatment, a randomised phase II 
trial is studying pemetrexed versus observation in patients with 
stable disease after first-line treatment. 
Clinical trials of targeted treatments
The presence of growth factor receptors in mesothelioma has 
prompted research into targeted therapies.
Epithelial growth factor receptor tyrosine 
kinase inhibitors
Epithelial growth factor receptor (EGFR) is often overexpressed 
in mesothelioma. However, phase II trials of the EGFR tyrosine 
kinase inhibitors erlotinib and gefitinib have not reported 
objective responses.
Vascular endothelial growth factor inhibitors
Vascular endothelial growth factor (VEGF) is an autocrine 
growth factor which induces new blood vessel formation. High 
concentrations of VEGF are associated with a poorer prognosis 
in mesothelioma. In phase II trials the antiangiogenic drugs 
bevacizumab, sorafenib and sunitinib have been relatively well 
tolerated, but have produced generally low response rates.10 
There was no advantage when bevacizumab was added to 
cisplatin and gemcitabine.11 A randomised phase II/III trial 
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(IFCT-GFPC-0701) of cisplatin and pemetrexed with or without 
bevacizumab as first-line treatment reported superior outcomes 
for the bevacizumab arm12 and so recruitment will continue to 
complete the phase III trial.
Histone deacetylase inhibitors
Histone deacetylase inhibitors, such as sodium valproate, 
activate transcription of genes involved in apoptosis, cell 
proliferation and angiogenesis. Trials of sodium valproate in 
patients with progressive disease found some biological activity. 
numerous newer drugs in this class are in testing including a 
phase III trial of vorinostat.
Ranpirnase
Ranpirnase is a ribonuclease which disrupts protein translation. 
It showed disease modifying activity by stabilising progressive 
disease, but a phase III trial of adding ranpirnase to adriamycin 
showed no overall survival advantage.
Proteasome inhibitors
The transcription factor nF-κΒ regulates proteins associated 
with evasion of apoptosis. Proteasome inhibitors interfere with 
degradation of inhibitor-κB, and so restore apoptosis. Two 
phase II studies of bortezomib are in progress.
Mammalian target of rapamycin inhibitors
Loss of a tumour suppressor in mesothelioma activates the 
mammalian target of rapamycin (mToR), a serine threonine 
kinase. This enzyme is highly expressed in mesothelioma, 
providing a rationale for evaluation of mToR inhibitors such as 
rapamycin itself (sirolimus) and analogues temsirolimus and 
everolimus (currently in phase II trial).
Imatinib
Signalling by platelet derived growth factor receptor promotes 
mesothelioma growth. Imatinib mesylate, an inhibitor of the 
enzyme associated with this receptor, was ineffective as a single 
drug, but increased tumour xenograft uptake of other anticancer 
drugs by its effect on tumour endothelium. There is now a 
phase II trial of gemcitabine plus imatinib.
Vascular disrupting drugs
These drugs target the established tumour vasculature causing 
tumour ischaemia and necrosis. They include small molecules 
of two classes – flavonoids and tubulin binding drugs. A trial of 
a tubulin binding drug BnC105P in mesothelioma is registered 
with the Australasian Lung Cancer Trials Group and is currently 
enrolling patients in multiple centres (the B2P2M2 trial).
Thalidomide
Thalidomide has anti-angiogenesis and other complex 
antitumour activity. There is a collaborative Dutch and 
Australian trial which is studying pemetrexed-based 
chemotherapy with or without maintenance thalidomide.
Novel first-line drugs
Mesothelin is a cytoplasmic membrane glycoprotein involved 
in cell adhesion and is proposed as a diagnostic and treatment 
response biomarker for mesothelioma. An anti-mesothelin 
monoclonal antibody Morab-009 (amatuximab) is in phase II  
trial. Also being studied are an anti-mesothelin antibody 
conjugated with pseudomonas exotoxin A, and a mesothelin 
vaccine designed to elicit an antibody dependent cytotoxicity 
response against mesothelin expressing tumour cells.
palliative management
Effective palliative management of mesothelioma often requires 
multiple interventions to alleviate symptoms of dyspnoea due 
to recurrent pleural effusion or lung encasement, pain due to 
parietal pleural irritation or intercostal nerve compression or 
invasion, and anorexia cachexia syndrome. An excellent review 
of palliative care for mesothelioma13 and randomised trials of 
palliative interventions are available to guide the management 
of common problems, including several studies of pleural 
drain site irradiation,14 pleurodesis versus partial pleurectomy, 
and thoracoscopic versus closed pleurodesis. new methods 
for managing repetitive drainage of recurring effusions in 
ambulatory patients using tunnelled pleural catheter systems 
are also available.
Regular medical follow-up with assessment of physical, 
psychological and social problems and action to address these 
is fundamental to effective management. Patients with thoracic 
pain due to mesothelioma require treatment with sustained 
release opioids and other analgesics with regular review of 
dosage, effectiveness, and pre-emptive management of adverse 
effects, particularly nausea, vomiting and constipation. Several 
studies report effective pain relief in over 50% of patients treated 
with radiation therapy.15 When pain is not readily relieved 
referral to a specialist pain management service is advisable. 
Advanced pain relief measures, including adjuvant treatment 
for neuropathic pain, nerve blocks, neurolytic procedures and 
epidural delivery of opioids and anaesthetics, can provide 
effective pain management. Glucocorticoids may be beneficial 
for anorexia and cachexia. 
Recognition and management of depression is essential and 
an important element of good palliative care is identification 
of various sources of social and psychological stress, which 
can include those encountered in applying for compensation. 
Fortunately for Australians occupationally exposed to asbestos, 
this process has been simplified by previous litigation. 
Engagement of specialist oncology and palliative care services, 
medical social worker, psychologist and other specialists is 
frequently needed to help patients cope with symptoms of 
mesothelioma.
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Future
The goal of establishing highly effective therapy for 
mesothelioma remains elusive, but multiple promising avenues 
towards this goal are opening. Personalised therapeutic 
approaches under investigation in mesothelioma include use 
of the ERCC1 gene as a predictor of poor response to platinum 
therapies and elevated thymidilate synthase as a predictor 
of reduced pemetrexed activity. one study found varying 
levels of in vitro chemoresistance in 168 cell lines generated 
from resected tumours.16 If this information predicts clinical 
response, it may help in future to identify the most effective 
treatment with the least amount of toxicity for an individual 
patient. 
Conclusion
There is no cure for malignant mesothelioma. Radical 
treatments remain unproven by randomised controlled clinical 
trial, and only a minority of patients are eligible for such 
therapy. Although platinum with antifolate chemotherapy is 
effective in prolonging survival and improves quality of life, it 
is not without toxicity and is not curative. Effective palliation for 
symptomatic disease requires an active pre-emptive approach. 
Vigorous research efforts are still required to discover effective 
treatment or secondary prevention strategies for a disease with 
an increasing worldwide incidence.  
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Self-test questions
The following statements are either true or false  
(answers on page 159)
5. Patients treated with pemetrexed and cisplatin need 
regular injections of vitamin B12.
6. Compared to cisplatin alone, cisplatin with pemetrexed 
increases the median survival of patients with 
mesothelioma by 12 months.
